<DOC>
	<DOCNO>NCT02041104</DOCNO>
	<brief_summary>The purpose study investigate daily consumption barley beta-glucans impact lipid glucose metabolism intestinal microbiota population metabolic syndrome . It assume two month intervention beta-glucans improve clinical sign metabolic syndrome alter composition intestinal microbiota . Variation microbiota composition investigate emphasis Bacteroidetes Firmicutes ratio . Furthermore presupposed consumption beta-glucans stimulate growth beneficial intestinal bacteria genus Lactobacillus Bifidobacteria consequently effect production short chain fatty acid population metabolic syndrome . Moreover presuppose two-month consumption beta-glucans influence glucose metabolism consequently improve insulin resistance within people metabolic syndrome . It assume two-month consumption beta-glucans improve specific plasma lipid content population metabolic syndrome .</brief_summary>
	<brief_title>Impact Consumption Beta-glucans Intestinal Microbiota Glucose Lipid Metabolism</brief_title>
	<detailed_description>In study investigate whether daily consumption barley beta-glucans integrate bread product effect lipid glucose metabolism alter composition intestinal microbiota population metabolic syndrome . 70 participant metabolic syndrome enrol study . Participants daily consume 200 g bread high amount beta-glucans . Hypothesis : 1 . Two-month consumption beta-glucans alters composition intestinal microbiota change ratio bacteria phylum Bacteroidetes Firmicutes . Furthermore consumption beta-glucans stimulate growth beneficial intestinal bacteria genus Lactobacillus Bifidobacteria consequently effect production short chain fatty acid population metabolic syndrome . 2 . Two-month consumption beta-glucans influence glucose metabolism consequently improve insulin resistance within people metabolic syndrome . 3 . Two-month consumption beta-glucans improve specific plasma lipid content population metabolic syndrome . Study design double blind , randomise , placebo control clinical trial perform regard CONSORT 2010 recommendation randomise clinical trial . Patient enrollment perform several community health centre Slovenia association family medicine doctor . Appropriate patient metabolic syndrome suggested participate clinical trial . Candidates suggest participate two month study . If recruit enough participant two month study suggest participation one month study . Candidates interested participate study inform study design term condition study main investigator . Study perform successful recruitment first 20 participant . Study perform three time , 70 participant recruit complete study . Participants consume bread high beta-glucans content ( around 3 , 4 g beta-glucans per 100 g bread ) 8 week period . Before begin study participant two week washout period without consume pre- pro-biotics . They remain usual eating habit study period except take antibiotic pre- pro-biotic . Participants give blood stool sample day intervention barley beta-glucans . Blood sample involve oral glucose test insulin resistance determination sample specific lipid content determination . They also option give blood sample genetic investigation gene associate lipid metabolism ( apoE ) . Blood stool sample repeat day intervention period . The parameter intervention period except genetic analysis investigate . 72-hour dietary recall perform intervention period individually evaluate daily nutrient energetic input participant .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Obesity , Abdominal</mesh_term>
	<criteria>Inclusion Criteria parameter use metabolic syndrome determination accord International Diabetes Federation ( IDF ) consensus worldwide definition Metabolic Syndrome : Participant must central obesity : defined waist circumference ≥ 80 cm European woman ≥ 94 cm European men . Beside central obesity candidate participate study must total cholesterol concentration ≥ 5,5 mmol/l enter study . Plus two follow four factor : HDLcholesterol content : man ≤ 1,03 mmol/ , woman ≤ 1,23 mmol/l Triglycerides content ≥ 1,7 mmol/l Fasting blood glucose ≥ 5,6 mmol/l Hypertension : systolic blood pressure ≥ 130 mm Hg diastolic blood pressure ≥ 85 mm Hg Diabetes type II Thyroid disorder Kidney disorder Antibiotic treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Two month intervention</keyword>
	<keyword>Randomised placebo control parallel study</keyword>
	<keyword>Beta-glucans</keyword>
	<keyword>Abdominal fat</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Gut Microbiota Composition</keyword>
	<keyword>Oral Glucose Tolerance Test</keyword>
	<keyword>Lipid Profile</keyword>
	<keyword>Real-Time Polymerase Chain Reaction</keyword>
	<keyword>Denaturating Gradient Gel Electrophoresis</keyword>
</DOC>